BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 150-159

  Huang, Shengbing ^a   Okumura, Kenji ^a   Sinicrope, Frank A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; BH3 PROTEIN; BIM PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DEATH RECEPTOR; LIPOCORTIN 5; MITOCHONDRIAL PROTEIN; OBATOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL LABELING; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INCUBATION TIME; LENTIVIRINAE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASES; CELL LINE, TUMOR; CYTOCHROMES C; HUMANS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 58849086028     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1575     Document Type: Article

References (38)

1. Reed JC Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 2006;3:388-98.
2. Jiang X, Wang X. Cytochrome c-mediated apoptosis. Annu Rev Biochem 2004;73:87-106.
3. Labi V, Erlacher M, Kiessling S, Villunger A. BH3- only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ 2006;13:1325-38.
4. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004;1644:83-94.
5. Annis MG, Soucie EL. Dlugosz PJ, et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J 2005;24: 2096-103.
6. Dlugosz PJ, Billen LP, Annis MG, et al. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J 2006;25:2287-96.
7. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22: 8628-33.
8. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17: 1675-87.
9. BroaddusVC, DansenTB, Abayasiriwardana KS, et al. Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem 2005;280: 12486-93.
10. Li H. Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491 -501
11. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94: 481-90.
12. Desagher S, Osen-Sand A, Nichols A, et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 1999:144:891 -901.
13. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 2000;20:929-35.
14. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res 2004;10:8284-92.
15. Sun SY, Yue P, Zhou JY, et al. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 2001;280: 788-97.
16. Reed JC. Proapoptotic multidomain Bcl-2/Bax- family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 2006;13: 1378-86.
17. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy Oncogene 2007; 26:1324-37.
18. Oltersdorf T, Elmore SW, Shoemaker AR. et al An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677 81.
19. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2. family proteins. Cell Death Differ 2006;13 1419- 21.
20. van Delft MF, Wei AH, Mason KD, et al The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389 - 99.
21. Nguyen M, Marcellus RC, Roulston A. et al Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 2007 104:19512-7.
22. Miyamoto Y, Hosotani R, Wada M, et al Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, Mcl-1 ex pression in pancreatic cancers Oncology 1999;56: 73-82.
23. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008;68:2944 51.
24. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bel inhibitor obatoclax (GX015-070) in multiple myeloma Blood 2007;109:5430-8.
25. Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007; 109:4441 -9.
26. Kepp O, Rajalingam K, Kimmig S, Rudel T. Bak and Bax are non-redundant during infection- and DNA damage-induced apoptosis. EMBO J 2007;26:825-34.
27. Vahsen N, Cande C, Briere JJ, et al. AIF deficiency compromises oxidative phosphorylation. EMBO J 2004;23:4679-89.
28. Konopleva M, Watt J, Contractor R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008;68:3413-20.
29. Takahashi Y, Karbowski M, Yamaguchi H, et al. Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Mol Cell Biol 2005;25: 9369-82.
30. Adjei A A, Davis JN, Bruzek LM, Erlichman C, Kauf- mann SH. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 2001;7:1438-45.
31. Wang P, Zhang J, Bellail A, et al. Inhibition of RIP and c-FLIP enhancesTRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 2007;19:2237-46.
32. Chou TC, Talalay P. Quantitative analysis of dose- effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
33. Slee EA, Keogh SA, Martin SJ. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ 2000;7:556-65.
34. Cande C, Vahsen N, Garrido C, Kroemer G. Apoptosisinducing factor (AIF): caspase-independent after all. Cell Death Differ 2004;11:591 -5.
35. xl, but not Bcl- 2, until displaced by BH3-only proteins. Genes Dev 2005;19:1294-305.
36. Czabotar PE, Lee EF, van Delft MF, et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A 2007;104: 6217-22.
37. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67:1176-83.
38. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000;7:1166-73.